Markets:

Overview

News

Currencies

International

Treasuries

Royalty Pharma plc - Class A Ordinary Shares (NQ:RPRX)

47.33 +0.30 (+0.63%)

Streaming Delayed Price Updated: 12:49 PM EDT, Mar 26, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about Royalty Pharma plc - Class A Ordinary Shares

< Previous 1 2 3 4 5 6 7 8 9 Next >

The Brain Barrier Broken: Inside Denali Therapeutics’ Landmark FDA Approval of AVLAYAH

Today 10:07 EDT

On March 25, 2026, the landscape of neurodegenerative medicine underwent a seismic shift. The U.S. Food and Drug Administration (FDA) granted accelerated approval to Denali Therapeutics (NASDAQ: DNLI)...

Via Finterra

Topics Economy Initial Public Offering

Royalty Pharma (RPRX): Buy, Sell, or Hold Post Q4 Earnings?

March 25, 2026

Royalty Pharma has had an impressive run over the past six months. While the S&P 500 has been flat, the stock has returned 31.5% and now trades at $45.91. Th...

Via StockStory

Topics Artificial Intelligence Stocks Supply Chain

ROYALTY PHARMA PLC-CL A (NASDAQ:RPRX) Shows High Technical and Setup Ratings Ahead of Potential Breakout ↗

March 18, 2026

Via Chartmill

3 Healthcare Stocks Walking a Fine Line

February 18, 2026

From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. Shareholders who bet on the industry have been rewarded lately as healthcare...

Via StockStory

Topics Stocks

Royalty Pharma PLC-CL A (NASDAQ:RPRX) Shares Dip Despite Strong Portfolio Growth and 2026 Guidance Beat ↗

February 11, 2026

Via Chartmill

Why Is TEVA Stock Rising Pre-Market Today? ↗

January 12, 2026

Via Stocktwits

5 Insightful Analyst Questions From Royalty Pharma’s Q4 Earnings Call

February 18, 2026

Royalty Pharma’s fourth quarter results did not meet Wall Street’s revenue or earnings expectations, with management attributing the performance to a combination of gradual product transitions in key...

Via StockStory

Topics Earnings

Patient Capital Bet Heavily on Chime Financial (CHYM) With a 2.04 Million Share Purchase ↗

February 14, 2026

Chime Financial delivers digital-first, fee-free banking solutions for U.S. consumers seeking accessible, low-cost financial services.

Via The Motley Fool

Royalty Pharma (RPRX) Q4 2025 Earnings Transcript ↗

February 11, 2026

Royalty Pharma (RPRX) Q4 2025 Earnings Transcript

Via The Motley Fool

Topics Bonds

Earnings Scheduled For November 5, 2025 ↗

November 05, 2025

Via Benzinga

Royalty Pharma (NASDAQ:RPRX) Reports Sales Below Analyst Estimates In Q4 CY2025 Earnings

February 11, 2026

Healthcare royalties company Royalty Pharma (NASDAQ:RPRX) fell short of the market’s revenue expectations in Q4 CY2025 as sales rose 4.7% year on year to $622 million. Its GAAP profit of $0.64 per...

Via StockStory

What To Expect From Royalty Pharma’s (RPRX) Q4 Earnings

February 09, 2026

Healthcare royalties company Royalty Pharma (NASDAQ:RPRX) will be reporting results this Wednesday morning. Here’s what to expect.

Via StockStory

Topics World Trade

3 Mid-Cap Stocks We Keep Off Our Radar

February 05, 2026

Mid-cap stocks have the best odds of scaling into $100 billion corporations thanks to their tested business models and large addressable markets. But the many opportunities in front of them attract...

Via StockStory

3 Profitable Stocks with Open Questions

January 20, 2026

Even if a company is profitable, it doesn’t always mean it’s a great investment. Some struggle to maintain growth, face looming threats, or fail to reinvest wisely, limiting their future potential.

Via StockStory

Branded Pharmaceuticals Stocks Q3 Results: Benchmarking Royalty Pharma (NASDAQ:RPRX)

January 07, 2026

The end of the earnings season is always a good time to take a step back and see who shined (and who not so much). Let’s take a look at how branded pharmaceuticals stocks fared in Q3, starting with...

Via StockStory

Topics Artificial Intelligence Intellectual Property

3 Overrated Stocks We Steer Clear Of

December 31, 2025

The stocks featured in this article have all approached their 52-week highs. When these price levels hit, it typically signals strong business execution, positive market sentiment, or significant...

Via StockStory

3 Healthcare Stocks We’re Skeptical Of

December 16, 2025

Personal health and wellness is one of the many secular tailwinds for healthcare companies. Shareholders who bet on the industry have been rewarded lately as healthcare stocks have returned 15.6% over...

Via StockStory

Topics Stocks

What's going on in today's after hours session ↗

December 08, 2025

After the conclusion of the US market's regular session on Monday, let's examine the after-hours session and unveil the notable performers among the top gainers and losers.

Via Chartmill

Royalty Pharma PLC-CL A (NASDAQ:RPRX) Shows Strong Technical Setup for a Breakout ↗

December 06, 2025

Royalty Pharma (RPRX) shows a strong technical breakout setup with a perfect 10/10 trend score and a 9/10 formation score, signaling a potential upward move.

Via Chartmill

3 Mid-Cap Stocks That Concern Us

December 03, 2025

Mid-cap stocks often strike the right balance between having proven business models and market opportunities that can support $100 billion corporations. However, they face intense competition from...

Via StockStory

Why Ligand Pharma, A Hidden Name Behind Two Big Drugs, Is Up 88% This Year ↗

November 18, 2025

Shares of Ligand Pharmaceuticals are absolutely flying as investors line up behind the company's unique royalty-based model.

Via Investor's Business Daily

3 Value Stocks with Warning Signs

November 17, 2025

Value stocks typically trade at discounts to the broader market, offering patient investors the opportunity to buy businesses when they’re out of favor. The key risk, however, is that these stocks are...

Via StockStory

Topics Supply Chain

3 Low-Volatility Stocks We Find Risky

November 16, 2025

A stock with low volatility can be reassuring, but it doesn’t always mean strong long-term performance. Investors who prioritize stability may miss out on higher-reward opportunities elsewhere.

Via StockStory

Royalty Pharma (RPRX): Buy, Sell, or Hold Post Q3 Earnings?

November 12, 2025

Royalty Pharma trades at $39.59 and has moved in lockstep with the market. Its shares have returned 20.6% over the last six months while the S&P 500 has gained 16.4%.

Via StockStory

Topics Stocks Supply Chain

Ligand Pharmaceuticals Soars to New Heights: A Deep Dive into its 52-Week High

November 06, 2025

San Diego, CA – November 6, 2025 – Ligand Pharmaceuticals (NASDAQ: LGND) has recently captured the financial spotlight, with its stock hitting a remarkable 52-week high of $197.78 on November 6, 2025....

Via MarketMinute

Topics Intellectual Property

Stocks Rebound, Eli Lilly Jumps To 14-Month Highs: What's Moving Markets Wednesday? ↗

November 05, 2025

Wall Street bounced back Wednesday after Tuesday's sharp selloff in AI-driven stocks, as investors bought the dip amid solid corporate earnings and growing signs that the Federal Reserve may be nearing...

Via Benzinga

Topics Economy

Royalty Pharma (NASDAQ:RPRX) Q3 2025 Earnings Beat Estimates and Raise Guidance ↗

November 05, 2025

Royalty Pharma's Q3 2025 earnings beat estimates, with strong revenue and EPS. The company also raised its full-year 2025 guidance.

Via Chartmill

Topics Earnings

Spotting Winners: Royalty Pharma (NASDAQ:RPRX) And Branded Pharmaceuticals Stocks In Q2

November 03, 2025

Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at Royalty Pharma (NASDAQ:RPRX) and the best...

Via StockStory

Topics Artificial Intelligence Intellectual Property

What To Expect From Royalty Pharma’s (RPRX) Q3 Earnings

November 03, 2025

Healthcare royalties company Royalty Pharma (NASDAQ:RPRX) will be reporting earnings this Wednesday before the bell. Here’s what to look for.

Via StockStory

Topics Artificial Intelligence

ROYALTY PHARMA PLC-CL A (RPRX) Shows Strong Technicals and a High-Quality Breakout Setup ↗

November 01, 2025

RPRX stock shows strong technical momentum and a high-quality consolidation pattern, signaling a potential breakout above key resistance.

Via Chartmill

< Previous 1 2 3 4 5 6 7 8 9 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.